Overall survival in renal-cell carcinoma with pazopanib versus sunitinib

N Engl J Med. 2014 May 1;370(18):1769-70. doi: 10.1056/NEJMc1400731.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / mortality
  • Disease-Free Survival
  • Follow-Up Studies
  • Humans
  • Indoles / therapeutic use*
  • Kaplan-Meier Estimate
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / mortality
  • Pyrimidines / therapeutic use*
  • Pyrroles / therapeutic use*
  • Sulfonamides / therapeutic use*
  • Sunitinib

Substances

  • Angiogenesis Inhibitors
  • Indoles
  • Pyrimidines
  • Pyrroles
  • Sulfonamides
  • pazopanib
  • Sunitinib